TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Child or adolescent patients must be at least 6 years of age, but must not yet have reached their 16th birthday prior to Visit 1, when informed consent is obtained.~2. Patients must meet the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition Text Revision (DSM-IV-TR) diagnostic criteria for ADHD. For the purposes of this study the diagnosis of ADHD will be confirmed during Visit 1 by administering the K-SADS-PL. Patients must also have an ADHDRS-IV-Parent:Inv score at least 1.5 standard deviations above the age norm for their diagnostic subtype at both Visit 1 and Visit 2. In addition, they must have a CGI-ADHD-S score 4 at both Visit 1 and Visit 2.~3. Patients must have a newly diagnosed case of ADHD. Newly diagnosed case of ADHD means that a specialist (including pediatrician, child psychiatrist, or child neurologist) or child psychologist has diagnosed ADHD (according DSM-IV-TR or International Statistical Classification of Diseases and Related Health Problems \[World Health Organisation; 10th Revision\] \[ICD 10\] criteria) within 3 months prior to Visit 1.~Exclusion Criteria:~1. Patients with history of ADHD diagnosis longer than 3 months prior to Visit 1. Diagnosis of ADHD means that a specialist (including pediatrician, child psychiatrist, or child neurologist) or child psychologist has diagnosed ADHD (according DSM-IV-TR or ICD 10 criteria) and has registered it in medical records or verbally informed parents about this diagnosis.~2. Patients who weigh less than 20 kg at study entry (Visit 1). If a patient's weight changes after Visit 1 to a value outside of the stated range, the patient will still be eligible, and the weight should be rounded to the nearest value within the above range for dosing purposes.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): atomoxetine: 0.5 mg/kg/day every day (QD),by mouth (PO) for 2 weeks, 1.2 - 1.4 mg/kg/day QD, PO for 10 weeks, then 1.2 - 1.4 mg/kg/day QD, PO for up to 1 year
- Placebo (Type: PLACEBO_COMPARATOR): placebo every day (QD), by mouth (PO) for 12 weeks,then possibility to switch to atomoxetine at 0.5 mg/kg/day QD, PO for 1 week, then to 1.2 - 1.4 mg/kg/day QD, PO for up to 1 year (open-label extension)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preservative-free Topical Anesthetics for Post-PRK Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients who are candidate for PRK surgery with~1. Myopia up to - 6 diopters or myopic astigmatism up to - 4 diopters.~2. Corneal thinnest pachymetry of 500 µm~3. Residual stromal bed more than 350 µm after epithelial ablation.~Exclusion Criteria:~Patients with~1. Corneal scars or dry eye disease,~2. Past ocular surgery,~3. History of contact lens wear,~4. Systemic diseases such as diabetes mellitus and autoimmune diseases,~5. History of oral analgesics abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Preservative-free topical anesthetics group (Type: EXPERIMENTAL): Patients in this group had the standard post-PRK treatment regimen in addition to the prescription of preservative-free topical anesthetics for pain control following single-step transepithelial PRK surgery in one eye.
- Preservative-free artificial tears group (Type: PLACEBO_COMPARATOR): Patients in this group had the standard post-PRK treatment regimen in addition to the prescription of preservative-free artificial tears as a placebo following single-step transepithelial PRK surgery in the other eye.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Completed treatment in one of two double-blind, placebo controlled studies of PEG-uricase in subjects with hyperuricemia and symptomatic gout~Exclusion Criteria:~* unstable angina~* uncontrolled arrhythmia~* uncontrolled hypertension~* end stage renal disease requiring dialysis~* anemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- q2 RCT (Type: EXPERIMENTAL): Pegloticase every 2 wk arm of Randomized Controlled Trial(RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
- q4 RCT (Type: EXPERIMENTAL): Pegloticase every 4 wk arm of Randomized Controlled Trial (RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
- Placebo in RCT (Type: EXPERIMENTAL): Placebo arm in Randomized Controlled Trial (RCT), received pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in OLE

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. ages between 18 and 65;~2. current acute unipolar depression episode;~3. total capacity to understand and respond to self-applied instruments;~4. the presence of symptoms in the last 30 days;~5. abstinence for at least 30 days for drug addicts~Exclusion Criteria:~1. presence of Organic Brain Syndrome (OBS);~2. pregnancy or lactation;~3. criteria for psychiatric hospitalization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sertraline (Type: EXPERIMENTAL): Group Started: sertraline (50mg-200mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with sertraline (50-200mg). Non responsive patients: 2nd step.~Second step: Sertraline 200mg + lithium (900mg-1500mg)~Non responsive patients: 3rd step.~Third step: Nortriptyline 100mg~Non responsive patients: 4th step.~Fourth step: Nortriptyline 100mg + lithium (900mg-1500mg)~Non responsive patients : 5th step~Fifth step : Nortriptyline 100mg + sertraline 200mg Non responsive patients~sixth step: Nortriptyline 100mg + sertraline 200mg + Lithium ( 900mg- 1500mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women 18 years old or older of any ethnic background~* Subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines), or the at home diagnostic test, and have been diagnosed with OSA~Exclusion Criteria:~* Pregnant or Breastfeeding women~* Women of Child Bearing Potential who are not willing to undergo methods to prevent pregnancy~* Subjects who are on medications that affect cardiac autonomic function (eg. Beta Blockers)~* Active smokers~* Subjects who are unable to read or answer questions in the English language

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Visit 1 Randomization (Type: EXPERIMENTAL): At visit 1 (PSG 1) subjects will receive one of two interventions: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.
- Visit 2: Crossover Randomization (Type: EXPERIMENTAL): At visit 2 (PSG 2) subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Oral Supplementation With Branched-Chain Amino Acids (BCAA) Improves Postoperative Quality of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who underwent elective liver resection for the treatment of hepatocellular carcinoma or adenocarcinoma with chronic liver diseases.~Exclusion Criteria:~* Body weight loss greater than 10 per cent during the 6 months prior to surgery,~* The presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal or heart disease.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aminolaban EN (Type: EXPERIMENTAL): Aminoleban EN™ was administered at a dose of 100 g per day commencing two weeks prior to surgery. A 100 g dose of Aminoleban EN™ contains 13.0 g of free amino acids, 13.0 g of gelatin hydrolysate, 1.0 g of casein, 62.1 g of carbohydrate, 7.0 g of lipid, glycyrrhizin, and other components, producing 420 kcal. The AEN group included 40 patients who were administered 100 g of Aminoleban EN™ as 50 g during the day and 50 g as a late evening snack.
- Control (Type: NO_INTERVENTION): The patients were divided into two groups including one group administered Aminoleban (the AEN group) and a control group given no additional dietary supplementation. The total caloric energy intake per day during the study period was assumed to be equal to Aminolaban EN group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of episodic migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.1 or 1.2) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to screening, migraine onset prior to age 50 and MONTHLY frequency of 4-14 Migraine Headache Days (MHD).~Exclusion Criteria:~* Are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product.~* Current use or prior exposure to Galcanezumab or another CGRP antibody.~* Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to Galcanezumab.~* History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Galcanezumab 120mg (Type: EXPERIMENTAL): Galcanezumab given by subcutaneous (SC) injection at 120mg dose once a month for 6 months. Participants received a loading dose of 240mg (2 injections of 120mg each) was administered at visit 3 only.
- Galcanezumab 240mg (Type: EXPERIMENTAL): Galcanezumab 240mg given by SC injection once a month for 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given by SC injection once a month for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* must be diagnosed as having active rheumatoid arthritis~* agree to participate in the study and sign and informed consent document~Exclusion Criteria:~* History of serious infection within the past 6 months~* test positive for TB~* have any uncontrolled clinically significant disease or laboratory tests~* require administration of prohibited medications during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient indicated for Spinal Cord Stimulation therapy in accordance with the approved labeling.~2. Patient's pain profile indicates appropriate lead placement would be at one or more levels from T7 to T10, to achieve pain coverage.~3. Patient has a baseline score on the Numerical Rating Scale ≥6 over the past 24 hours for 'average overall pain'specific to the area(s) of chronic pain that will be treated with spinal cord stimulation.~4. Patient is considered by the Study Investigator as a candidate for implantation of a spinal cord stimulator system according to the system Instructions for Use.~5. Patient is \>18 years of age at the time of enrollment.~6. Patient is willing to adhere to the study requirements, including compliance with and completion of all study visits.~7. Patient has signed and received a copy of the Ethical Committee/Independent Review Board approved informed consent.~Exclusion Criteria:~1. Patient currently has a spinal cord stimulation system implanted.~2. Patient has previously failed a spinal cord stimulation therapy (either trial system evaluation or permanent system implant).~3. Patient has a primary diagnosis of Peripheral Vascular Disease (PVD), Angina Pectoris, or Chronic Migraine.~4. Patient is scheduled to undergo an on-the-table trial evaluation (aka all-in-one procedure)~5. Patient is scheduled to be implanted with (a) surgical paddle trial lead(s).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (AB) (Type: ACTIVE_COMPARATOR): Group 1 (AB): anatomic lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
- Group 2 (TB) (Type: ACTIVE_COMPARATOR): Group 2 (TB): targeted lead placement followed by BurstDR™ stimulation during an initial trial evaluation period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study for Patients With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of osteoporosis~* No other severe disabling conditions~* Should have at least 1 vertebral or non-vertebral prevalent fracture, and bone mineral density T-score should be less than -2.5~* Ambulatory~* Men (aged 40 to 85 years) or postmenopausal women (aged 55 to 85 years)~Exclusion Criteria:~* History of a disease that affects bone metabolism~* History of treatment with any drug that may significantly affect bone metabolism~* History or presence of liver disease~* History or presence of kidney disease~* History of excessive alcohol drinking or drug abuse

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Primary Total Knee Arthroplasty for osteoarthritis Informed consent given~Exclusion Criteria~Current or treatment with IV Vancomycin within preceding 7 days Previous hypersensitivity to vancomycin Significant cardiac or respiratory abnormality Patient has contraindications to IO vascular access using the EZ-IO

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vancomycin 15mg/kg IV (Type: ACTIVE_COMPARATOR): Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery.
- Vancomycin 500mg Intraosseous (Type: EXPERIMENTAL): Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combining N-of-1 Trials to Assess Fibromyalgia Treatments

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who meet fibromyalgia criteria as defined by the American College of Rheumatology~* No systemic illness (current or past) or other contraindications to taking study medications (e.g. known hypersensitivity)~* Age 18-60~* Patient willingness, and physician agreement, to discontinue CNS medications/NSAIDs/analgesics for 1 week prior to starting their trial~* Patient informed consent and agreement to participate in an N-of-1 trial~Exclusion Criteria:~* Patients who are currently pregnant or who plan to become pregnant during the study period~* Patients with any contraindications to using either amitriptyline or fluoxetine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients received each intervention multiple times in random-order crossover design.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histological confirmed diagnosis cancer~* symptomatic malignant ascites~* EpCAM positive tumor~* EOCG 0-2~* negative pregnancy~Exclusion Criteria:~* acute or chronic infection~* exposure to investigational product, cancer chemo- or radiotherapy within the last 28 days~* previous treatment with mouse monoclonal antibodies~* known or suspected hypersensitivity to Removab or similar antibodies~* inadequate renal function~* inadequate hepatic function (AST, ALt, GTP,\< x ULN; bilirubin \<1.5xULN)~* Platelets \> 80000 cells/mm3; absolute neutrophil count (ANC) \< 1500 cells/mm3~* BMI \< 17~* Patients with reduced nutritional status~* Ileus within the last 30 days~* Brain metastases in cancer history~* Pregnant and nursing women~* history of myocardial infarction, congestive heart failure or relevant cardiac arrhythmia within previous 3 months~* inadequate respiratory function in option of investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 Catumaxomab (Type: ACTIVE_COMPARATOR): Patient received Catumaxomab and paracentesis
- 2: (Type: NO_INTERVENTION): Patient treated by paracentesis alone, but after the second paracentesis the patient is able to cross-over in the Catumaxomab-arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete